Table 2.
Splitting of the data into training, validation and test sets.
| Groups | Data split | Normal | HHD | HCM | ALCA |
|---|---|---|---|---|---|
| 1 | Training set | 91 | 19 | 32 | 13 |
| 2 | 91 | 19 | 32 | 13 | |
| 3 | 91 | 18 | 32 | 14 | |
| 4 | 91 | 19 | 32 | 13 | |
| 5 | Validation set | 91 | 19 | 31 | 14 |
| 6 | Test set | 91 | 18 | 32 | 14 |
| Total (n = 930) | 545 | 112 | 191 | 81 | |
Total study population was split into 6 groups, of which 4 groups were designated as the training set, and remaining 2 groups designated as the validation and test sets, respectively.
AF atrial fibrillation, BMI body-mass index, ALCA light-chain cardiac amyloidosis, EDD end-diastolic dimension, EDV end-diastolic volume, EF ejection fraction, ESD end-systolic dimension, ESV end-systolic volume, HHD hypertensive heart disease, HCM hypertrophic cardiomyopathy, IVSd interventricular septum at end-diastole, LVPWd left ventricular posterior wall thickness at end-diastole, LVWTmax end-diastolic maximal LV wall thickness, LA left atrium, LAVI left atrial volume index, LV left ventricular, MI mass index, N/A not applicable, PASP pulmonary artery systolic pressure, TR tricuspid regurgitation.